Silexion Therapeutics Corp. has announced a 1-for-10 reverse share split, set to take effect after market close on May 28, 2026. This means that for every ten shares currently held, shareholders will receive one new share. The company aims to strengthen its position on the Nasdaq Capital Market as it prepares for the upcoming Phase 2/3 trial of its cancer treatment, SIL204, targeting locally advanced pancreatic cancer. By increasing the share price, Silexion hopes to attract a broader range of investors and reduce market volatility.

This move is significant for people interested in the future of cancer treatments, particularly those with KRAS-driven cancers, which currently have limited options. Silexion’s focus on developing innovative therapies could potentially improve outcomes for patients facing these challenging diagnoses. The company’s previous trials showed a positive trend compared to standard chemotherapy, indicating that SIL204 may offer a new avenue for treatment as it advances through clinical testing.

The reverse share split is a strategic decision that reflects Silexion’s commitment to maintaining compliance with Nasdaq’s listing requirements and enhancing its capital structure. While this is a common practice among companies looking to stabilize their stock price, it is important to note that the effectiveness of SIL204 in clinical settings is still being evaluated. The upcoming trials will provide more concrete evidence of its potential benefits for patients.

For those following Silexion’s journey, it’s a reminder of the ongoing developments in cancer treatment. Keeping an eye on the results from the Phase 2/3 trial could provide insights into new therapeutic options for difficult-to-treat cancers.

Source: globenewswire.com